There was nothing rudimentary about Folding@Home (either in the MD engine or the MSM clustering method), and my paper on GPCRs that used Folding@Home regularly gets cites from pharma (we helped establish the idea that treating proteins as being a single structure at the global energy minimum was too simplistic to design drugs). But F@H was never really a serious attempt at drug discovery- it was intended to probe the underlying physics of protein folding, which is tangentially related.
In drug discovery, we'd love to be able to show that virtual screening really worked- if you could do docking against a protein to find good leads affordably, and also ensure that the resulting leads were likely to pass FDA review (IE, effective and non-toxic), that could potentially greatly increase the rate of discovery.
They do! Their research page is well worth checking out, they wrote a lot of the fundamental papers that people cite for machine learning today: https://research.nvidia.com/publications
> Will we finally compute for drug development and achieve just as great results as with chatbots?
Maybe - but they're not really analogous problem spaces. Fooling humans with text is easy - Markov chains have been doing it for decades. Automating the discovery of drugs and research of proteins is not quite so easy, rudimentary attempts like Folding@Home went on for years without any breakthrough discoveries. It's going to take a lot more research before we get to ChatGPT levels of success. But tools like CUDA certainly help with this by providing flexible compute that's easy to scale.